Sofinnova Investments’s Immunome IMNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$37.2M Buy
1,701,904
+83,427
+5% +$1.86M 1.41% 25
2025
Q4
$34.8M Buy
1,618,477
+1,182,426
+271% +$20.8M 1.5% 22
2025
Q3
$5.11M Sell
436,051
-342,425
-44% -$3.41M 0.28% 53
2025
Q2
$7.24M Sell
778,476
-10,190
-1% -$83.5K 0.44% 47
2025
Q1
$5.31M Buy
788,666
+41,842
+6% +$401K 0.35% 51
2024
Q4
$7.93M Buy
746,824
+70,058
+10% +$847K 0.58% 38
2024
Q3
$9.89M Buy
676,766
+21,086
+3% +$300K 0.79% 29
2024
Q2
$7.93M Buy
655,680
+61,284
+10% +$959K 0.41% 47
2024
Q1
$14.7M Buy
+594,396
New +$12.1M 0.82% 32

Other funds holding IMNM

Sofinnova Investments's IMNM Position: Q1 2026 in Review

Sofinnova Investments increased its Immunome (IMNM) stake by 5.2% in Q1 2026, buying an estimated $1.86M and bringing the position to 1,701,904 shares worth $37.2M. The position accounts for 1.41% of the portfolio, ranked #25.

Sofinnova Investments first reported a position in IMNM in Q1 2024 and has held it in 9 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Sofinnova Investments held 1,701,904 shares of Immunome worth $37.2M as of Q1 2026.
  • Sofinnova Investments bought 83,427 Immunome shares in Q1 2026, an estimated $1.86M.
  • Immunome made up 1.41% of Sofinnova Investments's portfolio in Q1 2026, its #25 holding.
  • Sofinnova Investments first reported a position in Immunome in Q1 2024 and has held it in 9 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.